CSBR Stock Analysis: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$5.81
-0.01 (-0.17%)
▼
5d:
-0.68%
30d:
+1.57%
90d:
+1.04%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 22, 2026
7d
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CSBR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: CSBR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $5.81, which is considered slightly low relative to its 30-day fair value range of $5.77 to $6.47. The stock's valuation (Forward PE: 58.1) is in line with its historical norms (57.4). At these levels, the market is pricing in 0.4% annual earnings growth.
Technical Outlook: Technically, CSBR is in a downtrend. Immediate support is located at $5.60, while resistance sits at $7.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+106.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CSBR is in a downtrend. Immediate support is located at $5.60, while resistance sits at $7.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+106.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.77 -
$6.47
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 106.5% below Wall St target ($12.00)
- BULLISH: Expecting earnings turnaround to 0.4% growth with -2.8% revenue growth
Trading Range Analysis
30-Day Trading Range
$5.77 -
$6.47
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.60
Resistance Level
$7.00
Current Trend
Downtrend
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
58.10
Wall Street Target
$12.00
(+106.5%)
Revenue Growth (YoY)
-2.8%
Earnings Growth (YoY)
-61.1%
Profit Margin
-4.0%
Valuation Premium vs History
+0.4% premium
PE vs Historical
58.1 vs 57.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.4%
(market-implied from PE analysis)
1-Year Target
$5.83
(+0%)
2-Year Target
$5.86
(+1%)
3-Year Target
$5.88
(+1%)
3-Yr Target (if PE normalizes)
(PE: 58→57)
PE COMPRESSION
$5.81
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 58.1, Growth: -16.7%)
$4.24
(+-27%)
Base:
(SPY PE: 21.8, Growth: -16.7%)
$1.59
(-73%)
Bear:
(PE: 18.5, Growth: -16.7%)
$1.35
(-77%)
Share & Embed Analysis
Last updated: July 14, 2026 3:58 AM ET
Data refreshes hourly during market hours. Next update: 4:58 AM
Data refreshes hourly during market hours. Next update: 4:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 60 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
